Want to see KALA full AI Analyst Report?
Top Page
KALA BIO
(NASDAQ:KALA)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.18
▼(-78.29% Downside)
Action:Reiterated
Date:10/15/26
The score is pressured primarily by very weak financial performance (near-zero revenue, ongoing losses, and significant cash burn) and strongly bearish technical signals (price well below moving averages with negative momentum). Corporate events are mixed, with delisting risk offsetting a positive distribution agreement, while valuation is constrained by loss-making status and no dividend support.
Positive Factors
Debt-free balance sheet
Eliminating debt reduces fixed financial obligations and lowers leverage-related risk compared with prior years. Positive equity also provides some balance-sheet support, giving Kala Bio greater flexibility to pursue operations and strategic initiatives without servicing a debt burden.
Negative Factors
No meaningful revenue base
Near-zero revenue means Kala Bio is not currently demonstrating operating scale or recurring commercial traction. Substantial losses despite the absence of meaningful sales weaken earnings visibility and leave future financial performance dependent on developing or commercializing viable offerings.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Eliminating debt reduces fixed financial obligations and lowers leverage-related risk compared with prior years. Positive equity also provides some balance-sheet support, giving Kala Bio greater flexibility to pursue operations and strategic initiatives without servicing a debt burden.
Read all positive factors
KALA BIO (KALA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.67M
Dividend YieldN/A
Average Volume (3M)2.70M
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue GrowthN/A
EPS Growth78.25%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume585,280
30 Day Avg. Volume2,697,987
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-1.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit131.49
Enterprise Value/Ebitda0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
KALA BIO Business Overview & Revenue Model
Company Description
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating...
How the Company Makes Money
Revenue sources tied to Kala Bio’s historical business model are null. As a clinical-stage biotechnology company for much of its operating history, the company’s funding and cash inflows would typically come from financing activities (e.g., issuin...
KALA BIO Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.89M | 11.24M |
| Gross Profit | -54.00K | 0.00 | -259.00K | -303.00K | 1.33M | 7.14M |
| EBITDA | -8.79M | -23.39M | -32.47M | -36.08M | -37.02M | -133.25M |
| Net Income | -10.08M | -26.98M | -38.51M | -42.20M | -44.82M | -142.60M |
Balance Sheet | ||||||
| Total Assets | 10.58M | 9.49M | 55.48M | 55.95M | 86.82M | 139.43M |
| Cash, Cash Equivalents and Short-Term Investments | 7.23M | 7.56M | 51.18M | 50.90M | 70.50M | 92.14M |
| Total Debt | 0.00 | 0.00 | 32.25M | 36.32M | 42.95M | 80.19M |
| Total Liabilities | 1.54M | 2.49M | 43.15M | 48.45M | 67.85M | 122.62M |
| Stockholders Equity | 9.04M | 7.00M | 12.33M | 7.50M | 18.97M | 16.80M |
Cash Flow | ||||||
| Free Cash Flow | -19.86M | -31.99M | -29.59M | -28.54M | -79.22M | -109.12M |
| Operating Cash Flow | -19.86M | -31.99M | -29.38M | -27.93M | -78.91M | -108.23M |
| Investing Cash Flow | -15.00K | -15.00K | -208.00K | -429.00K | 62.72M | 70.80M |
| Financing Cash Flow | -4.85M | -11.62M | 29.88M | 8.51M | -7.94M | 42.55M |
KALA BIO Technical Analysis
Negative
0.82
Price Trends
0.54
Negative
1.08
Negative
7.92
Negative
Market Momentum
-0.11
Positive
19.08
Positive
33.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KALA, the sentiment is Negative. The current price of 0.82 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.54, and below the 200-day MA of 7.92, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 19.08 is Positive, neither overbought nor oversold. The STOCH value of 33.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KALA.
KALA BIO Risk Analysis
KALA BIO disclosed 67 risk factors in its most recent earnings report. KALA BIO reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
KALA BIO Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.46M | -0.19 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $12.91M | -0.06 | -254.62% | ― | -97.99% | 99.28% | |
44 Neutral | $13.53M | -0.87 | -748.08% | ― | ― | ― | |
41 Neutral | $6.54M | -0.77 | -237.91% | ― | ― | 23.05% | |
39 Underperform | $3.67M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
KALA
KALA BIO
0.19
-38.92
-99.51%
DARE
Daré Bioscience
0.69
-1.40
-67.08%
HIND
Vyome Holdings
1.84
-3.69
-66.73%
CTXR
Citius Pharmaceuticals
0.40
-1.33
-77.03%
LEXX
Lexaria Bioscience
2.82
-10.83
-79.34%
XCUR
Exicure
1.01
-3.73
-78.69%
KALA BIO Corporate Events
Business Operations and Strategy
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal
Positive
Sep 10, 2026
On September 3, 2026, Kala Bio entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc., under which Kala became the sole distributor and reseller of Virotek’s genetic testing and clinical screening program for ophtha...
Regulatory Filings and ComplianceShareholder Meetings
KALA BIO Updates Annual Meeting and Proposal Deadlines
Neutral
Sep 9, 2026
On September 9, 2026, KALA BIO’s Board of Directors set November 3, 2026 as the date for the company’s next annual meeting of stockholders, advancing it by more than 30 days from the prior year’s meeting date. The company will la...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
KALA BIO Faces Nasdaq Listing Compliance Uncertainty
Negative
Aug 28, 2026
On August 27, 2026, KALA BIO disclosed that it received a Nasdaq Staff Determination Letter stating its common stock had closed below $1.00 for 30 consecutive business days from July 16 to August 26, 2026, violating the exchange’s minimum bi...
Private Placements and FinancingRegulatory Filings and Compliance
Kala Bio Files Prospectus Supplement for New Securities Offering
Neutral
Jul 23, 2026
On July 22, 2026, Kala Bio filed a prospectus supplement under Rule 424(b) to facilitate an offering of securities under its previously effective shelf registration statement on Form S-3. In conjunction with this filing, the company submitted a le...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.